The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI
-
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
Cyber Resilience and Recovery Amid Evolving Cyber Threats
Data durability is a key aspect of NIST’s cybersecurity framework for public and private organizations.
21m listen -
How Tech Enables Environmental Justice at EPA
The agency wants to eliminate bias and establish new tech standards to reduce greenhouse gas emissions.
39m listen -
Building Better Data Governance Across FDA
The agency is using emerging technology to tackle its data challenges.
19m listen -
Coast Guard Poised for Growth in Cyber
The service’s prevention policy chief discusses his priorities for combatting cyber incidents that could have global impacts.
23m listen